Clinical Trials
No Objective Responses With Ulixertinib (Investigational) in BRAF Fusions or Non-V600 Tumors
Subbiah et alClinical Cancer Research

Subprotocol Z1L (EAY131-Z1L) of the NCI-MATCH ECOG-ACRIN trial evaluated the clinical activity of the oral ERK1/2 inhibitor ulixertinib in heavily pretreated patients whose tumors harbored non-V600 BRAF mutations or BRAF fusions, alterations known to confer dependence on the RAF–MEK–ERK pathway. In this single-arm study, patients received ulixertinib orally at 600 mg twice daily continuously across 28-day cycles until disease progression or intolerable toxicity. The primary endpoint was objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), 6-month PFS, and overall survival (OS).
The cohort consisted of 34 eligible patients with a median age of 66.5 years; 50% were women, and race distribution was 88% White, 9% Black, and 3% Asian. Most patients (74%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 1, and the median number of prior therapies was 4. Represented cancer types included gastrointestinal malignancies (n = 16), lung cancer (n = 3), melanoma (n = 3), and other tumor types.
The study met with negative efficacy results: no patients achieved a complete response or partial response, resulting in an ORR of 0%. Stable disease was recorded as the best response in 7 of 26 centrally confirmed cases. Secondary survival endpoints showed a median PFS of 1.7 months (90% confidence interval [CI], 1.1–2.2), a 6-month PFS rate of 5% (90% CI, 0.6%–17.7%), and a median OS of 3.5 months (90% CI, 1.9–5.4).
Safety evaluations showed that 20 patients (57%) had grade 3 toxicity and 1 patient (3%) experienced grade 4 toxicity as their worst toxicity, with no grade 5 toxicities reported. The authors concluded that ulixertinib had no demonstrable evidence of clinical activity in this small, heavily pretreated population with BRAF fusions or non-V600E/non-V600K BRAF mutations.
Key Takeaways
- Ulixertinib yielded an objective response rate of 0% with no complete or partial responses, while stable disease was achieved as the best response in 7 of 26 centrally confirmed cases.
- Survival outcomes included a median progression-free survival of 1.7 months (90% CI, 1.1–2.2), a 6-month progression-free survival rate of 5% (90% CI, 0.6%–17.7%), and a median overall survival of 3.5 months (90% CI, 1.9–5.4).
- Worst-grade adverse events included grade 3 toxicity in 57% of patients (n = 20) and grade 4 toxicity in 3% (n = 1), with no grade 5 toxicities observed.
Read the original sourceClinical Cancer Research
